HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nickel allergy-promoting effects of microbial or inflammatory substances at the sensitization step in mice.

Abstract
Microbial components stimulate innate immunity via Toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), and/or IL-1. We recently reported that in mice, Escherichia coli lipopolysaccharide (LPS, TLR4-ligand) promotes allergic responses to nickel (Ni) at both the sensitization and elicitation steps. Here, we examined in mice the effects of administering other microbial or inflammatory materials at the Ni-sensitization step. A mixture of 1mM NiCl(2) and a test solution was injected into BALB/c mice intraperitoneally (0.1 ml/10 g body weight), and 10 days later 5mM NiCl(2) was challenged intradermally into the ear pinnas of the mice (20 μl/ear). The following preparations or substances exhibited adjuvant activities: Prevotella intermedia LPS, Saccharomyces cerevisiae mannan, a synthetic muramyl dipeptide (NOD2-stimulating cell-wall component of bacteria), Pam(3)Cys-SKKKK (TLR2-stimulating synthetic peptide), poly I:C (TLR3-stimulating double-stranded RNA), concanavalin A (a typical T-cell mitogen and T-cell-mediated hepatitis-inducer), heat-killed Propionibacterium acnes (Gram-positive bacterium that causes pimples and induces macrophage-mediated experimental hepatitis), and nitrogen-containing bisphosphonates (chemicals stimulating IL-1 production). Unexpectedly, P. intermedia LPS, which displayed the most potent adjuvant activity among the tested preparations, was effective in TLR4-dysfunctional mutant mice, but not in TLR2-deficient mice, whereas the reverse was true for S. cerevisiae mannan. These results suggest that (i) for the establishment of Ni-allergy in mice, stimulation of innate immunity (including TLRs, NLRs, IL-1 production, and/or other factors) may be important at the sensitization step, and (ii) P. intermedia may produce a substance(s) that potently promotes Ni-allergy via stimulation of TLR2.
AuthorsHarue Takahashi, Masayuki Kinbara, Naoki Sato, Keiichi Sasaki, Shunji Sugawara, Yasuo Endo
JournalInternational immunopharmacology (Int Immunopharmacol) Vol. 11 Issue 10 Pg. 1534-40 (Oct 2011) ISSN: 1878-1705 [Electronic] Netherlands
PMID21621645 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Elsevier B.V. All rights reserved.
Chemical References
  • Adjuvants, Immunologic
  • Dipeptides
  • Inflammation Mediators
  • Interleukin-1
  • Lipopolysaccharides
  • Lipoproteins
  • Mannans
  • Tlr2 protein, mouse
  • Tlr4 protein, mouse
  • Toll-Like Receptor 2
  • Toll-Like Receptor 4
  • Concanavalin A
  • Acetylmuramyl-Alanyl-Isoglutamine
  • Nickel
  • 2,3-bis-(palmitoyloxy)-2-propyl-N-palmitoyl-cysteinylserine
  • Poly I-C
Topics
  • Acetylmuramyl-Alanyl-Isoglutamine (administration & dosage)
  • Adjuvants, Immunologic (administration & dosage)
  • Animals
  • Concanavalin A (administration & dosage)
  • Dipeptides (administration & dosage)
  • Hypersensitivity, Delayed (chemically induced, immunology)
  • Immunity, Innate (drug effects)
  • Immunization
  • Inflammation Mediators (administration & dosage)
  • Interleukin-1 (genetics, immunology, metabolism)
  • Lipopolysaccharides (administration & dosage)
  • Lipoproteins (administration & dosage)
  • Mannans (administration & dosage)
  • Mice
  • Mice, Inbred Strains
  • Mice, Knockout
  • Mutation (genetics)
  • Nickel (administration & dosage)
  • Poly I-C (administration & dosage)
  • Prevotella intermedia (immunology)
  • Propionibacterium acnes (immunology)
  • Saccharomyces cerevisiae (immunology)
  • Toll-Like Receptor 2 (agonists, genetics)
  • Toll-Like Receptor 4 (agonists, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: